Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q1 FY26 Earnings Presentation
17 slides from Eris Lifesciences's earnings presentation, Aug 5, 2025
Slide 1: Exchange filing cover letter: Investor Presentation
EY Entrepreneur of the yea,2013 FROST & SULLIVAN Best Practices-2013 ElusIness today(YES bank Excellence Awards-2013 Eris Eris Lifesciences Limited Date: Date: 05 05 August August 2025 2025 To To To To BSE Limited BSE Limited National National Stock Exchange of Stock Exchange ofIndia India Limited L
Slide 2: Q1 FY26 Investor Presentation
Eris ERIS LIFESCIENCES LIMITED Q1 FY Q1 FY 26 26 INVESTOR PRESENTATION INVESTOR PRESENTATION 5th Aug 5th Aug 2025 2025 1 Eris
Slide 3: Business and Financial Highlights – Q1 FY26
BUSINESS AND BUSINESS AND FINANCIAL FINANCIALHIGHLIGHTS HIGHLIGHTS –- Q1 Q1 FY26 FY26 •• Domestic Domestic Branded Branded Formulations (DBF) business Formulations (DBF) businessgrows grows11% 11%--outperforms outperforms IPM*IPM* byby ~- 330 bps 330 bps •• DBF DBF growth growth ~- 13-14% 13-14% aft
Slide 4: Business and Financial Highlights – Q1 FY26
BUSI NESS AND BUSINESS FINANCIAL HIGH AND FINANCIAL HIGHLIGHTS Q1 FY26 LIGHTS –- Q1 FY26 DBF EBIDTA Margin Biocon segme Biocon nt EBIDTA segment EBID Margin DBF Revenue (Rs. Cr.) 702 37.2% 30% 155 bps 1100 bps 1100 bps 30% 11% 19% 19% 632 35.6% Q1 26 Q1 25 Q1 26 At Start At Start Q1 26 Q126 Q1 25 DB
Slide 5: Domestic Branded Formulations (DBF) – Insulin Business Update
• DOMESTIC BRANDED DOMESTIC BRANDED FORMULATIONS FORMULATIONS (DBF) (DBF) –- INSULIN INSULIN BUSINESS BUSINESS UPDATE UPDATE Insulin Key Insulin Key Updates Updates Insulin Vials Insulin Vials line line @ @ Bhopal Bhopal site site •• Insulin DS shortage Insulin DS solved; however, shortage solved; D
Slide 6: Domestic Branded Formulations (DBF) – GLP-1 Updates
DOMESTIC BRANDED DOMESTIC BRANDED FORMULATIONS FORMULATIONS (DBF) (DBF) –- GLP-1 GLP-1 UPDATES UPDATES Cartridge line Cartridge line under under installation installation at at Bhopal Bhopal Semaglutide key Semaglutide key updates updates •• In In line with our line with our expectation, expectation
Slide 7: DBF – Several Launches Expected from Our Small Molecule Pipeline
s DBF DBF -- SEVERAL SEVERAL LAUNCHES LAUNCHES EXPECTED EXPECTED FROM FROM OUR OUR SMALL SMALL MOLECULE MOLECULE PIPELINE PIPELINE Our (small Our (small molecule) R&D pipeline molecule) R&D going into pipeline going intoFY26 FY26 Q2 Q2 Launch Launch Zayo Trio Zayo Trio -–Corn Combipack bi pack of Sa
Slide 8: International Business – Clear Visibility of Impact from Investments
INTERNATIONAL BUSINESS INTERNATIONAL ... BUSINESS -- CLEAR CLEAR VISIBILITY OF IMPACT VISIBILITY OF FROM INVESTMENTS IMPACT FROM INVESTMENTS 1 •• At At the time of the time of acquisition, acquisition, Swiss Swiss Parenterals Parenterals had had a a 20+ 20+ year year legacy legacy in in injectable i
Slide 9: Significant Uptick Expected in Europe Revenues Starting FY27
SIGNIFICANT UPTICK SIGNIFICANT UPTICKEXPECTED EXPECTED IN IN EUROPE EUROPE REVENUES REVENUES STARTING FY27 STARTING FY27 Scope M Scope ofof signedcontracts signed contracts EU-CDMO Pipeline EU-CDMO Pipeline–- sample sample profiles profiles of of confirmed confirmed contracts contracts Covering most
Slide 10: International Business – Q1 Business and Financial Highlights
INTERNATIONAL BUSINESS INTERNATIONAL BUSINESS –- Q1 Q1 BUSINESS BUSINESS AND AND FINANCIAL FINANCIAL HIGHLIGHTS HIGHLIGHTS Revenue* --Rs. Revenue* Rs. Cr. Cr. (RoW (RoW business) business) Regulatory Updates Regulatory Updates 74 68 68 EU-GMP approval •• EU-GMP approval received received for for bot
Slide 11: Summary of Consolidated Financials – Q1 FY26
SUMMARY OF SUMMARY OF CONSOLIDATED CONSOLIDATEDFINANCIALS FINANCIALS–- Q1 Q1 FY26 FY26 Revenue (Rs. Cr.) Revenue (Rs. Cr.) "'Lim EBIDTA EBIDTA(Rs. (Rs. Cr.) Cr.) PAT (Rs. Cr.) • • 773 773 277 277 125 125 I 41% 7.4% 11% 89 89 720 720 250 250 Q1 25 Q125 Q1 26 Q126 Q1 25 Q125 Q1 26 Q126 Q1 25 Q125 Q1 2
Slide 12: We Reaffirm Our FY26 Net Debt to EBIDTA Target of 1.5x
• WE REAFFIRM WE REAFFIRM OUR OUR FY26 NET DEBT FY26 NET DEBT TO TO EBIDTA EBIDTA TARGET TARGET OF OF 1.5X 1.5X Plan an shared shared at at the start of the start of FY FY25 Outlook at the end of FY25 Debt Reduction Debt Reduction on on track track Debt to Debt toEBIDTA EBIDTA << 2x 2x by by 30th 30
Slide 13: Consolidated P&L Statement – Q1 FY26
CONSOLIDATED P&L CONSOLIDATED P&L STATEMENT STATEMENT -- Q1 Q1 FY26 FY26 Consolidated Consolidated Q1 FY Q1 26 FY26 Q1 FY Q1 26 FY26 Q1 Q1 FY FY 25 25 r INR INRCrores Crores yoyGr yoy Gr % % Revenue from Operations Revenue from Operations 773 773 720 720 7.4% 7.4% Consolidated operating •• Consolida
Slide 14: We Are on Track to Deliver on Our Strategic Priorities for FY26
WE ARE WE ARE ON ON TRACK TRACK TO TO DELIVER DELIVER ON ON OUR OUR STRATEGIC STRATEGIC PRIORITIES PRIORITIES FOR FOR FY26 FY26 Business Business Segment Segment Strategic priorities Strategic prioritiesfor forFY26 FY26 1 Anti-Diabetes Anti-Diabetes •• Leverage Leverage the market opportunity the ma
Slide 15: Shareholder Profile
SHAREHOLDER PROFILE SHAREHOLDER PROFILE Shareholding of Shareholding of Promoters Promoters and and Top Top 15 15 Institutional Institutional Investors Investors Shareholding Pattern Shareholding Pattern 30-Jun-25 30-Jun-25 31-Mar-25 31-Mar-25 31-Dec-24 31-Dec-24 Name of Name of Shareholder Sharehol
Slide 16: Safe Harbor Statement
SAFE HARBOR SAFE HARBOR STATEMENT STATEMENT This presentation This presentation contains contains forward-looking forward-looking statements statements and information that and information that involve involve risks, risks, uncertainties uncertainties and and assumptions. Forward-looking assumptions
Slide 17: Thank You
Eris ERIS LIFESCIENCES LIMITED THANK YOU THANK YOU KRUTI RAVAL KRUTI RAVAL INVESTOR INVESTOR RELATIONS RELATIONS kruti@erislifesciences.com kruti@erislifesciences.com 16 Eris Lifesciences